The development of immunologic products especially designed for fish is a science that has existed for a little over than 20 years. In spite of this, during this period of time laboratories have been able to design solutions for several diseases (see Table 2). However, there are still many challenges to be overcome, as explained in this report by different industry specialists.

Non-injectable vaccines for the Infectious Pancreatic Necrosis virus (IPN), Flavobacteriosis, and for creating a defense against fungosis, are some of the sector’s priorities. Also, avoiding unwanted secondary effects after applying immunologic products has become an important challenge for pharmaceutical laboratories, which have achieved important progress in these matters.

As to the offer of immunologic products for fresh water, the veterinarian of Trusal S.A., Joel Quidel commented that there is still no vaccine for Flavobacterioris and that only this year an immersion vaccine has been introduced for IPN, “whose results are still to be seen”. The specialist also expressed that an oral product is being used which, “although it has helped to reduce losses, it is not yet a definitive solution”. Quidel added that “these problems will probably tend to be eradicated with the increasing incorporation of recirculation fish farming, through the filtering and temperature handling technology.” Likewise, he believes that these technologies would partly solve the problem implied by fungosis, for which no vaccine has been developed.

The Sales and Marketing Manager of Agua de Novartis Chile S.A., Constantino Siderakis, is in agreement with these challenges, and added that “although therapeutic alternatives are available, it would be very innovative to introduce a biological product that prevents fungosis.” As regards oral alternatives for IPN, he pointed out that there are some restrictions for administering them to salmon and trout because “if not prepared with inactivated virus, they would be recombining proteins, that is, molecules that are easily destroyable when they come into contact with the fish’s digestive system.”

Complementation of treatments with biologic products and the use of therapies with nucleotides or immunostimulants, as well as implementation of strict bio-safety measures that collaborate with prevention, are other considerations with which experts are working today to prevent the outbreak of these diseases.

Namely because, according to different sources, the domestic salmon farming industry has to learn from the errors, success and good practices of animal industries with greater experience and trajectory, such as the poultry and porcine sectors. Meanwhile, it should continue focusing its efforts on better protecting its fry against IPN and seeking to extend to a maximum protection against Salmon Rickettsial Septicemia (SRS). At any rate, and as shown in this article, possibilities of prevention are constantly rising.

IX Región: La incubadora de la salmonicultura Nº 116

Artículo central
IX Región:
La incubadora de la salmonicultura
• • • • • • •

Producción
Un factor clave:
Eficiencias durante el alevinaje
• • • • • • •

Comercialización
Consumidores europeos de seafood:
Paladares exigentes
• • • • • • •

Salud
Para salmónidos
Disponibilidad de vacunas para agua dulce
• • • • • • •

Entrevista
Courtney Hough, secretario general de la FEAP:
“Se debe invertir en imagen”
• • • • • • •

Actualidad
IX Región: todos caben
• • • • • • •

Summary
Region IX:
An incubator for the fish farming industry
• • • • • • •

Summary
A key factor:
Efficiencies during fry growing
• • • • • • •

Summary
For salmon and trout
Availability of vaccines for freshwater stage
• • • • • • •

Summary
European seafood consumers
Have demanding tastes
• • • • • • •

Ver todas las
revistas publicadas